Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
CADTH
Record ID 32015000168
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that stiripentol be listed for use in combination with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome), whose seizures are not adequately controlled with clobazam and valproate alone, if conditions are met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0360_Diacomit_October_20_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anticonvulsants
- Child, Preschool
- Infant
- Infant, Newborn
- Seizures
- Epilepsies, Myoclonic
- Spasms, Infantile
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.